NAD on Slim 90
This article was originally published in The Tan Sheet
Executive Summary
Claims by NMD Marketing that the weight-loss product Slim 90 "is safe" and has "no side effects" will be referred to FTC, the National Advertising Division announces Dec. 1. NMD has not responded to NAD's "repeated attempts" to obtain substantiation for the claims, which are not compliant with a recent NAD decision, in which NMD agreed to suspend six efficacy, performance and safety claims that NAD determined were not backed by reliable scientific evidence (1"The Tan Sheet" June 14, 2004, p. 11)...
You may also be interested in...
Slim 90 Weight-Loss Claims Unsubstantiated, NAD Concludes
NMD Marketing should discontinue certain claims for its Slim 90 weight-loss product in the absence of "competent and reliable scientific evidence," according to the National Advertising Division of the Council of Better Business Bureaus
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.